Across TCGA pan-cancer cohorts, HS3ST3A1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HS3ST3A1 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher HS3ST3A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HS3ST3A1 expression acts as an unfavorable survival marker.
CESC, SARC, and GBM are the cancer types where HS3ST3A1 Mutation most reproducibly stratifies survival.